Cancer Research and Treatment

Original Articles

Genitourinary cancer

Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer: Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho; Cancer Res Treat. 2022;54(4):1191-1199. Published online December 7, 2021; DOI: https://doi.org/10.4143/crt.2021.985

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study proposed the optimal definition of biochemical recurrence (BCR) after salvage radiotherapy (SRT) following radical prostatectomy for prostate cancer.
Materials and Methods
Among 1,117 patients who had received SRT, data from 205 hormone-naïve patients who experienced post-SRT prostate-specific antigen (PSA) elevation were included in a multi-institutional database. The primary endpoint was to determine the PSA parameters predictive of distant metastasis (DM). Absolute serum PSA levels and the prostate-specific antigen doubling time (PSA-DT) were adopted as PSA parameters.
Results
When BCR was defined based on serum PSA levels ranging from 0.4 ng/mL to nadir+2.0 ng/mL, the 5-year probability of DM was 27.6%-33.7%. The difference in the 5-year probability of DM became significant when BCR was defined as a serum PSA level of 0.8 ng/ml or higher (1.0-2.0 ng/mL). Application of a serum PSA level of ≥ 0.8 ng/mL yielded a c-index value of 0.589. When BCR was defined based on the PSA-DT, the 5-year probability was 22.7%-39.4%. The difference was significant when BCR was defined as a PSA-DT ≤ 3 months and ≤ 6 months. Application of a PSA-DT ≤ 6 months yielded the highest c-index (0.660). These two parameters complemented each other; for patients meeting both PSA parameters, the probability of DM was 39.5%-44.5%; for those not meeting either parameter, the probability was 0.0%-3.1%.
Conclusion
A serum PSA level > 0.8 ng/mL was a reasonable threshold for the definition of BCR after SRT. In addition, a PSA-DT ≤ 6 months was significantly predictive of subsequent DM, and combined application of both parameters enhanced predictability.

Citations

Citations to this article as recorded by

Effects of silybin on triptorelin-induced bone metabolic abnormalities in prostate cancer revealed based on TMT-based proteomics
Jianhui Li, Xuejiao Lv, Ying Jiang, Sudarshan Kasireddy
PLOS One.2026; 21(1): e0341064. CrossRef
Beyond the tumor: recurrence-prone radiomics for prognostication in negative PSMA PET/CT scans of prostate cancer
Fereshteh Yousefirizi, Sara Harsini, Mobin Mohebi, Ian Alberts, Tahir Yusufaly, Monica Luo, Hamid Abdollahi, Elmira Yazdani, Soheila Mirabedin, Maziar Sabouri, Parham Geramifar, Peyman Sheikhzadeh, Patrick Martineau, Don Wilson, François Bénard, Carlos Ur
Biomedical Physics & Engineering Express.2026; 12(4): 045011. CrossRef
Expert consensus recommendations for the management of biochemical recurrence in prostate cancer: a Delphi study across clinical scenarios
Fernando López Campos, Felipe Couñago, Juan Antonio Vallejo, Antoni Vilaseca, Daniel Pérez Fentes
Clinical and Translational Oncology.2026;[Epub] CrossRef
New Prostate MRI Scoring Systems (PI-QUAL, PRECISE, PI-RR, and PI-FAB): AJR Expert Panel Narrative Review
Adriano B. Dias, Silvia D. Chang, Fiona M. Fennessy, Soleen Ghafoor, Sangeet Ghai, Valeria Panebianco, Andrei S. Purysko, Francesco Giganti
American Journal of Roentgenology.2025;[Epub] CrossRef
Biochemical recurrence after radical prostatectomy and postoperative radiotherapy: current evidence and controversial issues
Mattia Longoni, Fabian Falkenbach, Markus Graefen, Tobias Maurer, Pierre I. Karakiewicz, Francesco Montorsi, Alberto Briganti, Giorgio Gandaglia
Current Opinion in Urology.2025; 35(5): 510. CrossRef
Radiation Therapy for Local or Biochemical Recurrence Following Radical Prostatectomy in Patients with Prostate Cancer
Hiroki Nishiyama, Gen Kawaguchi, Kozue Ito, Go Hasegawa, Yohei Ikeda, Noboru Hara, Tsutomu Nishiyama
Research and Reports in Urology.2025; Volume 17: 327. CrossRef
Prostate-specific Antigen Nadir and Time to Nadir Predict Recurrence in Postprostatectomy Patients Treated with Salvage Radiotherapy Without Androgen Deprivation Therapy
Federico Mastroleo, Riccardo Villa, Mattia Zaffaroni, Maria Giulia Vincini, Ciro Franzese, Luca Nicosia, Fabio Matrone, Alessandra Donofrio, Alessandro Magli, Luca Triggiani, Salvina Barra, Giorgia Timon, Matteo Augugliaro, Vincenzo Burgio, Giulio Francol
European Urology Oncology.2025;[Epub] CrossRef
A Prospective Randomized Multicenter Study on the Impact of [18F]F-Choline PET/CT Versus Conventional Imaging for Staging Intermediate- to High-Risk Prostate Cancer
Laura Evangelista, Fabio Zattoni, Marta Burei, Daniele Bertin, Eugenio Borsatti, Tanja Baresic, Mohsen Farsad, Emanuela Trenti, Mirco Bartolomei, Stefano Panareo, Luca Urso, Giuseppe Trifirò, Elisabetta Brugola, Franca Chierichetti, Davide Donner, Lucia S
Journal of Nuclear Medicine.2024; 65(7): 1013. CrossRef
Comparison of the Effects of DOTA and NOTA Chelators on 64Cu-Cudotadipep and 64Cu-Cunotadipep for Prostate Cancer
Inki Lee, Min Hwan Kim, Kyongkyu Lee, Keumrok Oh, Hyunwoo Lim, Jae Hun Ahn, Yong Jin Lee, Gi Jeong Cheon, Dae Yoon Chi, Sang Moo Lim
Diagnostics.2023; 13(16): 2649. CrossRef

11,602 View
190 Download
8 Web of Science
9 Crossref

Clinical Outcomes of Postoperative Radiotherapy Following Radical Prostatectomy in Patients with Localized Prostate Cancer: A Multicenter Retrospective Study (KROG 18-01) of a Korean Population: Sung Uk Lee, Kwan Ho Cho, Won Park, Won Kyung Cho, Jae-Sung Kim, Chan Woo Wee, Young Seok Kim, Jin Ho Kim, Taek-Keun Nam, Jaeho Cho, Song Mi Jeong, Youngkyong Kim, Su Jung Shim, Youngmin Choi, Jun-Sang Kim; Cancer Res Treat. 2020;52(1):167-180. Published online June 25, 2019; DOI: https://doi.org/10.4143/crt.2019.126

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to investigate the clinical outcomes of postoperative radiotherapy (PORT) patients who underwent radical prostatectomy for localized prostate cancer.
Materials and Methods
Localized prostate cancer patients who received PORT after radical prostatectomy between 2001 and 2012 were identified retrospectively in a multi-institutional database. In total, 1,117 patients in 19 institutions were included. Biochemical failure after PORT was defined as prostate-specific antigen (PSA) ≥ nadir+2 after PORT or initiation of androgen deprivation therapy (ADT) for increasing PSA regardless of its value.
Results
Ten-year biochemical failure-free survival, clinical failure-free survival, distant metastasisfree survival, overall survival (OS), and cause-specific survival were 60.5%, 76.2%, 84.4%, 91.1%, and 96.6%, respectively, at a median of 84 months after PORT. Pre-PORT PSA ≤ 0.5 ng/ml and Gleason’s score ≤ 7 predicted favorable clinical outcomes, with 10-year OS rates of 92.5% and 94.1%, respectively. The 10-year OS rate was 82.7% for patients with a PSA > 1.0 ng/mL and 86.0% for patients with a Gleason score of 8-10. The addition of longterm ADT (≥ 12 months) to PORT improved OS, particularly in those with a Gleason score of 8-10 or ≥ T3b.
Conclusion
Clinical outcomes of PORT in a Korean prostate cancer population were very similar to those in Western countries. Lower Gleason score and serum PSA level at the time of PORT were significantly associated with favorable outcomes. Addition of long-term ADT (≥ 12 months) to PORT should be considered, particularly in unfavorable risk patients with Gleason scores of 8-10 or ≥ T3b.

Citations

Citations to this article as recorded by

Delayed Salvage Radiation Therapy Guided by Contrast-Enhanced Local and Whole-Body Diffusion-Weighted Magnetic Resonance Imaging During Prostate-Specific-Antigen-Based Surveillance After Radical Prostatectomy: A Retrospective Cohort Study
Tadashi Matsumoto, Shoji Morishita, Tomohiko Matsuyama, Kazuhiro Katahira, Yasuyuki Hamada, Kazumasa Hara, Shinsuke Hamada, Chikako Awazu, Takahiro Otsuka, Shigeo Yamada, Hirohito Otsuka, Takahiro Watakabe, Yoshiyuki Fukugawa, Natsuo Oya
Advances in Radiation Oncology.2026; 11(11): 102123. CrossRef
Optimal Definition of Biochemical Recurrence in Patients Who Receive Salvage Radiotherapy Following Radical Prostatectomy for Prostate Cancer
Sung Uk Lee, Jae-Sung Kim, Young Seok Kim, Jaeho Cho, Seo Hee Choi, Taek-Keun Nam, Song Mi Jeong, Youngkyong Kim, Youngmin Choi, Dong Eun Lee, Won Park, Kwan Ho Cho
Cancer Research and Treatment.2022; 54(4): 1191. CrossRef
A discussion on controversies and ethical dilemmas in prostate cancer screening
Satish Chandra Mishra
Journal of Medical Ethics.2021; 47(3): 152. CrossRef
Clinical Outcome of Salvage Radiotherapy for Locoregional Clinical Recurrence After Radical Prostatectomy
Sung Uk Lee, Kwan Ho Cho, Jin Ho Kim, Young Seok Kim, Taek-Keun Nam, Jae-Sung Kim, Jaeho Cho, Seo Hee Choi, Su Jung Shim, Jin Hee Kim, Ah Ram Chang
Technology in Cancer Research & Treatment.2021;[Epub] CrossRef

11,600 View
216 Download
4 Web of Science
4 Crossref

Postoperative Radiotherapy Alone Versus Chemoradiotherapy in Stage I-II Endometrial Carcinoma: An Investigational and Propensity Score Matching Analysis: Jong Hoon Lee, Hyo Chun Lee, Sung Hwan Kim, Mi Joo Chung, Song Mi Jeong, Sung Jong Lee, Joo Hee Yoon, Dong Choon Park; Cancer Res Treat. 2015;47(2):298-305. Published online September 15, 2014; DOI: https://doi.org/10.4143/crt.2014.038

Abstract PDF PubReader ePub

Purpose
The purpose of this study was to compare the results of postoperative adjuvant radiotherapy (RT) and concurrent chemoradiotherapy (CRT) in stage I-II endometrial carcinoma. Materials and Methods We analyzed a total of 64 patients with surgically staged I-II endometrial carcinoma who were treated with postoperative adjuvant RT or concurrent CRT between March 1999 and July 2013. Thirty-two patients who received postoperative RT alone were matched with those who received postoperative CRT (n=32) in accordance to age, stage, and tumor histology. Overall survival and relapse-free survival, as well as toxicity of the RT and CRT arms were evaluated and compared. Results The 5-year overall survival rate was 90.0% for the RT arm and 91.6% for the CRT arm. There was no significant difference in overall survival between the two treatment arms (p=0.798). The 5-year relapse-free survival rate was 87.2% in the RT arm and 88.0% in the CRT arm. Again, no significant difference in relapse-free survival was seen between the two arms (p=0.913). In a multivariate analysis, tumor histology was an independent prognostic factor for relapse-free survival (hazard ratio, 3.67; 95% of CI, 2.34 to 7.65; p=0.045). Acute grade 3 or 4 hematologic toxicities in the CRT arm were significantly higher than in the RT alone arm (6.2% vs. 31.2%, p=0.010). Conclusion Adjuvant pelvic concurrent chemoradioherapy did not show superior results in overall survival and relapse-free survival compared to RT alone in stage I-II endometrial carcinoma.

Citations

Citations to this article as recorded by

The prognostic and clinical significance of cervical stromal invasion in endometrial cancer: a multicenter retrospective study
Zhuang Li, Yang Yang, Yan Fang, Zhaoyang Zhang, Congjian Xu, Yang Li, Jihong Liu, Jianliu Wang, Qin Yao, Jieqing Zhang, Shuzhong Yao, Hongyan Guo, Yuehan Gao, Haocheng Zhang, Xiaoyu Yin, Xiaoke Liang, Zhihua Zong, Aijun Yin, Qing Zhang, Beihua Kong
American Journal of Obstetrics and Gynecology.2026; 234(5): 1416. CrossRef
Impacts of Postoperative Adjuvant Therapies on the Survival of Women with High-Risk Early-Stage Endometrial Cancer: A Cohort Study
Hee Joong Lee, Banghyun Lee
Cancers.2025; 17(2): 187. CrossRef
Adjuvant Therapy Use and Survival in Stage II Endometrial Cancer
Nataniel H. Lester-Coll, Melissa R. Young, Henry S. Park, Elena S. Ratner, Babak Litkouhi, Shari Damast
International Journal of Gynecological Cancer.2017; 27(9): 1904. CrossRef

15,583 View
108 Download
5 Web of Science
3 Crossref

First
Prev
Page of 1
Next
Last

Search